In addition to bladder cancer [14], EphA2 overexpression is observed in numerous indications, including non-small cell lung cancer (NSCLC) [15], breast cancer [16,17], gastric cancer [18], esophageal cancer [19], pancreatic carcinoma [20], colorectal cancer [21], prostate cancer [22], head and neck cancer [23], glioblastoma [24], and ovarian cancer [25]. Here, EPHA2 is linked to urinary bladder cancer.